A Multi-Element Expression Score Is A Prognostic Factor In Glioblastoma Multiforme.

Journal Article (Journal Article)

PURPOSE: Glioblastoma multiforme (GBM) is a highly malignant tumor of the central nervous system. Although primary GBM patients receive extensive therapies, tumors may recur within months, and there is no objective and scientific method to predict prognosis. Adoptive immunotherapy holds great promise for GBM treatment. However, the expression profiles of the tumor-associated antigens (TAAs) and tumor immune microenvironment (TME) genes used in immunotherapy of GBM patients have not been fully described. The present study aimed to develop a predictive tool to evaluate patient survival based on full analysis of the expression levels of TAAs and TME genes. METHODS: Expression profiles of a panel of 87 TAAs and 8 TME genes significantly correlated with poor prognosis were evaluated in 44 GBM patients and 10 normal brain tissues using quantitative real-time polymerase chain reaction (qRT-PCR). A linear formula (the LASSO algorithm based in the R package) weighted by regression coefficients was used to develop a multi-element expression score to predict prognosis; this formula was cross-validated by the leave-one-out method in different GBM cohorts. RESULTS: After analysis of gene expression, clinical features, and overall survival (OS), a total of 8 TAAs (CHI3L1, EZH2, TRIOBP, PCNA, PIK3R1, PRKDC, SART3 and EPCAM), 1 TME gene (FOXP3) and 4 clinical features (neutrophil-to-lymphocyte (NLR), number of basophils (BAS), age and treatment with standard radiotherapy and chemotherapy) were included in the formula. There were significant differences between high and low scoring groups identified using the formula in different GBM cohorts (TCGA (n=732) and GEO databases (n=84)), implying poor and good prognosis, respectively. CONCLUSION: The multi-element expression score was significantly associated with OS of GBM patients. The improve understanding of TAAs and TMEs and well-defined formula could be implemented in immunotherapy for GBM to provide better care.

Full Text

Duke Authors

Cited Authors

  • Li, J-Q; Wang, Q-T; Nie, Y; Xiao, Y-P; Lin, T; Han, R-J; Li, Z; Fan, Y-Y; Yuan, X-H; Wang, Y-M; Zhang, J; He, Y-W; Liao, H-X

Published Date

  • 2019

Published In

Volume / Issue

  • 11 /

Start / End Page

  • 8977 - 8989

PubMed ID

  • 31695490

Pubmed Central ID

  • PMC6805247

International Standard Serial Number (ISSN)

  • 1179-1322

Digital Object Identifier (DOI)

  • 10.2147/CMAR.S228174


  • eng

Conference Location

  • New Zealand